AdvanCell

AdvanCell is a clinical-stage radiopharmaceutical company founded in Sydney, Australia, in June 2019 by Andrew Adamovich, who currently serves as the CEO. Adamovich, who has a background in venture capital and had previously invested in nuclear medicine, identified an opportunity when large pharmaceutical companies began investing heavily in the field. The company was established to address a critical challenge in oncology: the scalable production of alpha-emitting isotopes for use in Targeted Alpha Therapies (TATs).

The company's core business revolves around its proprietary platform technology, which enables the reliable and scalable manufacture of Lead-212 (²¹²Pb), an isotope AdvanCell considers ideal for TAT due to its short 10.6-hour half-life and potent cancer-killing properties. This technology takes the form of a world-first Alpha Isotope Generator, which allows for daily, on-demand production of the isotope, named Alpha 212®. By controlling the isotope supply, AdvanCell operates a vertically integrated model, managing the entire radiopharmaceutical development lifecycle from isotope production and drug manufacturing to preclinical research and clinical development. This model is designed to accelerate the delivery of treatments to patients.

AdvanCell's primary product candidate is ADVC-001, a TAT designed to treat metastatic castration-resistant prostate cancer (mCRPC) by targeting the prostate-specific membrane antigen (PSMA). In November 2023, the company initiated its multicenter TheraPb Phase I/II clinical trial, dosing its first patient in Australia. Beyond prostate cancer, the company is developing a pipeline of therapies for other cancers, including melanoma, pancreatic, and breast cancer. Its business model involves both advancing its own pipeline and collaborating with major pharmaceutical companies. AdvanCell has entered into a strategic collaboration with Eli Lilly and Company to leverage its ²¹²Pb production technology for a broader portfolio of cancer treatments.

Since its inception, AdvanCell has achieved significant milestones, including securing substantial funding through multiple rounds. Notable financing includes an A$18 million Series B round in 2022 and an oversubscribed US$112 million (A$178 million) Series C round in February 2025. This funding supports the expansion of its 40,000-square-foot manufacturing facility in Brisbane and the acceleration of its clinical trials. The company has grown to a team of 60 and has established global partnerships and a strong investor base, including Morningside, SV Health Investors, Sanofi Ventures, and Brandon Capital.

Keywords: radiopharmaceuticals, Targeted Alpha Therapy, Lead-212, ²¹²Pb isotope, cancer treatment, oncology, ADVC001, metastatic prostate cancer, PSMA targeting, isotope production, clinical-stage biotech, Andrew Adamovich, TheraPb clinical trial, radioligand therapy, nuclear medicine, Alpha Isotope Generator, drug development, biopharmaceutical manufacturing, Morningside Ventures, Sanofi Ventures, SV Health Investors